AR021876A1 - Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado - Google Patents
Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegiladoInfo
- Publication number
- AR021876A1 AR021876A1 ARP990106462A ARP990106462A AR021876A1 AR 021876 A1 AR021876 A1 AR 021876A1 AR P990106462 A ARP990106462 A AR P990106462A AR P990106462 A ARP990106462 A AR P990106462A AR 021876 A1 AR021876 A1 AR 021876A1
- Authority
- AR
- Argentina
- Prior art keywords
- interferon alfa
- effective amount
- weeks
- hcv
- therapeutically effective
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se revela el uso de ribavirina e interferon alfa pegilado para la manufactura de composiciones farmacéuticas para tratar un paciente con infeccion cronicade hepatitis C, por ejemplo un paciente que tiene un genotipo 1,2 o 3 de VHC, para erradicar elARN del VHC detectable, mediante un método que comprende laadministracion de una cantidad efectiva de ribavirina en asociacion con una cantidad efectiva de interferon alfa pegilado, que se caracteriza en que eltratamiento de los pacientes que tieneninfecciones cronicas de hepatitis C se efectua en dos períodos de tratamiento;(a)un primer período de tratamiento de almenos 20 a 30 semanas, en el cual se administran una cantidad terapéuticamente efectiva de ribavirina y una cantidad dosificantede induccion terapéuticamenteefectiva de interferon alfa pegilado, por ejemplo, interferon alfa-2b pegilado suficiente para al menos disminuir sustanciamente, y preferentemente paraerradicar el ARN de VHC detectable; y b) un segundo período detratamie nto de al menos de 20 a 30 semanas, donde una cantidad terapéuticamente efectiva deribavirina y una cantidad terapéuticamente efectiva de interferon alfa pegilado se administran en forma suficiente para mantener el ARN del VHC nodetectable,durante a l menos de 20 a 30 semanas luego de finalizar el primer período de tratamiento y para mantener el ARN del VHC no detectable durante al menos 24semanas, luego de finalizar el segundo período de tratamiento.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21587698A | 1998-12-18 | 1998-12-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR021876A1 true AR021876A1 (es) | 2002-08-07 |
Family
ID=22804768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990106462A AR021876A1 (es) | 1998-12-18 | 1999-12-16 | Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1140143A2 (es) |
| JP (1) | JP2003507322A (es) |
| AR (1) | AR021876A1 (es) |
| AU (1) | AU2157000A (es) |
| CA (1) | CA2354536A1 (es) |
| PE (1) | PE20001369A1 (es) |
| WO (1) | WO2000037110A2 (es) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| JP5230052B2 (ja) | 2000-05-26 | 2013-07-10 | イデニクス（ケイマン）リミテツド | フラビウイルスおよびペスチウイルス治療のための方法および組成物 |
| EP1294888B1 (en) * | 2000-06-30 | 2007-04-25 | ZymoGenetics, Inc. | Interferon-like protein zcyto21 |
| US7208167B2 (en) | 2000-08-07 | 2007-04-24 | Sciclone Pharmaceuticals, Inc. | Treatment of hepatitis C with thymosin and peptide combination therapy |
| DK1311279T3 (da) * | 2000-08-07 | 2007-02-12 | Sciclone Pharmaceuticals Inc | Behandling af hepatitis C med thymosin, interferon og ribavirin |
| EP1326594A2 (en) * | 2000-10-18 | 2003-07-16 | Schering Corporation | Ribavirin-pegylated interferon alfa hcv combination therapy |
| CN101531715A (zh) | 2001-04-20 | 2009-09-16 | 津莫吉尼蒂克斯公司 | 细胞因子蛋白质家族 |
| US7910313B2 (en) | 2001-04-20 | 2011-03-22 | Zymogenetics, Inc. | Cytokine protein family |
| TW200500374A (en) | 2002-06-28 | 2005-01-01 | Idenlx Cayman Ltd | 2' and 3' -nucleoside produrgs for treating flavivridae infections |
| WO2004002422A2 (en) | 2002-06-28 | 2004-01-08 | Idenix (Cayman) Limited | 2’-c-methyl-3’-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
| US7608600B2 (en) | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
| CA2506129C (en) | 2002-11-15 | 2015-02-17 | Idenix (Cayman) Limited | 2'-branched nucleosides and flaviviridae mutation |
| WO2005003147A2 (en) | 2003-05-30 | 2005-01-13 | Pharmasset, Inc. | Modified fluorinated nucleoside analogues |
| EP1660116A4 (en) * | 2003-08-13 | 2008-04-30 | Smith Howard J & Ass Pty Ltd | METHOD FOR THE TREATMENT OF VIRUS INFECTIONS |
| CN101023094B (zh) | 2004-07-21 | 2011-05-18 | 法莫赛特股份有限公司 | 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备 |
| SI3109244T1 (sl) | 2004-09-14 | 2019-06-28 | Gilead Pharmasset Llc | Priprava 2'fluoro-2'-alkil-substituiranih ali drugih neobvezno substituiranih ribofuranozil pirimidinov in purinov in njihovih derivatov |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| CA2699280A1 (en) * | 2007-09-14 | 2009-03-26 | Schering Corporation | Method of treating hepatitis c patients |
| TW200946541A (en) | 2008-03-27 | 2009-11-16 | Idenix Pharmaceuticals Inc | Solid forms of an anti-HIV phosphoindole compound |
| CL2009002207A1 (es) | 2008-12-23 | 2011-02-18 | Gilead Pharmasset Llc | Compuestos derivados de 3-hidroxi-5-(9h-purin-9-il)tetrahidrofuran-2-il, inhibidor de la replicacion de arn viral dependiente de arn; composicion farmaceutica; uso para el tratamiento de hepatitis c. |
| SG172363A1 (en) | 2008-12-23 | 2011-07-28 | Pharmasset Inc | Synthesis of purine nucleosides |
| WO2010075517A2 (en) | 2008-12-23 | 2010-07-01 | Pharmasset, Inc. | Nucleoside analogs |
| US9198907B2 (en) | 2009-04-06 | 2015-12-01 | Ptc Therapeutics, Inc. | Combinations of a HCV inhibitor such as bicyclic pyrrole derivatives and a therapeutic agent |
| TWI583692B (zh) | 2009-05-20 | 2017-05-21 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| AP3515A (en) | 2010-03-31 | 2016-01-11 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| JP6069215B2 (ja) | 2010-11-30 | 2017-02-01 | ギリアド ファーマセット エルエルシー | 化合物 |
| UA116087C2 (uk) | 2011-09-16 | 2018-02-12 | Гіліад Фармассет Елелсі | Композиція для лікування вірусу гепатиту c |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| ES2527544T1 (es) | 2011-10-21 | 2015-01-26 | Abbvie Inc. | Tratamiento mono (PSI-7977) o de combinación con AAD para su uso en el tratamiento del VHC |
| AR088463A1 (es) | 2011-10-21 | 2014-06-11 | Abbvie Inc | Metodos para el tratamiento de hcv |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| KR20140119012A (ko) | 2013-01-31 | 2014-10-08 | 길리어드 파마셋 엘엘씨 | 두 항바이러스 화합물의 병용 제형물 |
| ES2900570T3 (es) | 2013-08-27 | 2022-03-17 | Gilead Pharmasset Llc | Formulación de combinación de dos compuestos antivirales |
| WO2017189978A1 (en) | 2016-04-28 | 2017-11-02 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6387365B1 (en) * | 1995-05-19 | 2002-05-14 | Schering Corporation | Combination therapy for chronic hepatitis C infection |
| US5908621A (en) * | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| EP1136075B1 (en) * | 1997-09-21 | 2003-01-15 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| BR9910505A (pt) * | 1998-05-15 | 2001-01-02 | Schering Corp | Terapia de combinação compreendendo ribavirina e interferon alfa em pacientes cândidos de tratamento antiviral tendo infecção crÈnica por hepatite c |
-
1999
- 1999-12-16 AR ARP990106462A patent/AR021876A1/es unknown
- 1999-12-16 WO PCT/US1999/027935 patent/WO2000037110A2/en not_active Application Discontinuation
- 1999-12-16 JP JP2000589220A patent/JP2003507322A/ja active Pending
- 1999-12-16 AU AU21570/00A patent/AU2157000A/en not_active Abandoned
- 1999-12-16 EP EP99965894A patent/EP1140143A2/en not_active Withdrawn
- 1999-12-16 CA CA002354536A patent/CA2354536A1/en not_active Abandoned
- 1999-12-17 PE PE1999001292A patent/PE20001369A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000037110A3 (en) | 2000-09-14 |
| EP1140143A2 (en) | 2001-10-10 |
| WO2000037110A2 (en) | 2000-06-29 |
| CA2354536A1 (en) | 2000-06-29 |
| JP2003507322A (ja) | 2003-02-25 |
| PE20001369A1 (es) | 2000-12-09 |
| AU2157000A (en) | 2000-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR021876A1 (es) | Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado | |
| CO4940414A1 (es) | Terapia de interferones polietilenglicol modificados | |
| HUP0103423A2 (hu) | Ribavirint és alfa-interferont tartalmazó kombinált terápia vírusellenes kezelésben nem részesült, krónikus hepatitis C fertőzött paciensek kezelésében | |
| ES2186660T3 (es) | Terapia de combinacion para erradicar hcv-rna detectable en pacientes con infeccion por hepatitis c cronica. | |
| AR021226A1 (es) | Terapia combinatoria con ribavirina-interferon alfa para erradicar el hcv-rna detectable en aquellos pacientes que presentan infeccion porhepatitis c cronica | |
| TW200716095A (en) | Method of treating interferon non-responders using HCV protease inhibitor | |
| BR0114636A (pt) | Terapia combinada para hcv de interferon-alfa peguilado/ribavirina | |
| BR9911076A (pt) | Uso de peg-ifn-alfa e ribavirina para o tratamento de hepatite c crÈnica | |
| PL1778272T3 (pl) | Zastosowanie kombinacji cyklosporyny i pegylowanych interferonów do leczenia zapalenia wątroby typu C (HCV) | |
| BR0009840A (pt) | Terapia de combinação para hcv, contendo ribavirina em associação com antioxidantes | |
| EA201000085A1 (ru) | dsPHK, ПРЕДНАЗНАЧЕННАЯ ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ИНФЕКЦИИ | |
| AR022116A1 (es) | Terapia de combinacion para el vhc por induccion de ribavirina - interferon alfa | |
| MD990258A (en) | Method of treatment of the acute viral hepatitis B | |
| MD2549F1 (en) | Method of treatment of the chronic viral hepatitis C | |
| CY1106388T1 (el) | Θepαπεια ηπατιτιδας c με θυμοσινη, ιντepφepονη και ριβαβιρινη | |
| JP2004529158A5 (es) | ||
| DK1311286T3 (da) | Behandling af hepatitis C med thymosin og pegyleret interferon | |
| ECSP993178A (es) | Terapia combinatoria con ribarvirina -interferon alfa para erradicar el hcv - rna detectable en aquellos pacientes que presentan infeccion por hepatitis c cronica | |
| TH33755A (th) | การรักษาร่วมเพื่อขจัด hcv-rna ที่ตรวจหาได้ในผู้ป่วยที่ติดเชื้อตับอักเสบ c เรื้อรัง | |
| TH53874A3 (th) | การบำบัดรักษา hcv แบบผสมผสานโดยการเหนี่ยวนำด้วยไรบาไวรินและอินเทอฟีรอนอัลฟาชนิดเพกิเลเตด | |
| FR2791894B1 (fr) | Utilisation d'interferon beta dans le traitement de la tumeur d'ewing | |
| ECSP982669A (es) | Terapia en combinacion para erradicar vhc -arn detectable en pacientes que padecen infeccion de hetatitis c cronica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |